BAY 60–6583 je selektivni agonistadenozinskogA2Breceptora.[4]
Pokazano je da pruža zaštitu od ishemije (nedostatka kiseonika usled blokade snabdevanja kiseonikom) u srcu i bubrezima test životinja,[5][6] i da je koristan u tretmanu akutnih povreda pluća.[7] On može da ima niz potencijalnih primena kao selektivni A2B agonist.
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signalling. 2008 Dec;4(4):287-303. PMID18443746
↑Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 Mar 27;115(12):1581-90. PMID17353435
↑Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Medicine. 2008 Jun 24;5(6):e137. PMID18578565
↑Eckle T, Grenz A, Laucher S, Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. Journal of Clinical Investigation. 2008 Oct;118(10):3301-15. PMID18787641